Open Road

Open Road Therapeutics is a pre-clinical stage biotechnology company dedicated to developing novel small molecule drugs that target RNA-binding proteins (RBPs) for the treatment of cancer. Founded by former AbbVie Chief Scientific Officer Thomas Hudson and oncology expert Sridhar Ramaswamy, the company focuses on a class of proteins that regulate gene expression and are often hijacked by cancer cells to promote growth and survival. By leveraging a proprietary discovery platform, Open Road aims to identify and inhibit specific RBPs that were previously considered "undruggable," offering new therapeutic options for patients with difficult-to-treat malignancies. The company is headquartered in the San Francisco Bay Area and operates primarily in early-development mode, advancing a pipeline of precision oncology candidates. Its approach combines deep expertise in genomics and cancer biology to address high-unmet-need indications.